2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy

Cytokine modulation and immune adjuvants have emerged as potent strategies in the development of effective cancer immunotherapy. These cytokines-interleukins, interferons, and growth factors-orchestrate immune signaling pathways to amplify anti-tumor responses while maintaining immune homeostasis. New delivery systems and engineered cytokine preparations achieve better therapeutic specificity and lower toxicity with prolonged immune activation. Similarly, immune adjuvants are under development, aimed at enhancing vaccine efficacy and improving the antigen presentation against cancer antigens for generating robust and durable immune responses.

This session will discuss recent advances in cytokine-based therapies, adjuvant design, and their combination with checkpoint inhibitors and cellular therapies during the Cancer Research and Development Conference 2026. Researchers will present clinical applications, safety optimization, and combination strategies that improve the immune system. Join us as we explore how cytokine modulation and immune adjuvants extend the frontiers of cancer immunotherapy and drive more potent and durable treatment outcomes.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno-Oncology and Cell-Based Therapies
Innovations in Immuno-Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy: Clinical Progress and Challenges
Next-Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next-Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody–Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy